ClinicalTrials.gg
Active, not recruitingNCT02791581UPBEATUpdated Sep 28, 2026

Understanding and Predicting Breast Cancer Events After Treatment

An interventional study of Cardiac MRI in Breast Cancer, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 66 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Prevention

How we know

Updated Sep 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
403
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in Breast Neoplasms by Wake Forest University Health Sciences — 5 open to participants now, 12 under way, none of them phase 3. Breast Neoplasms · Wake Forest University Health Sciences.

Enrollment
2nd of 49
403 · median 30
Started
2017
with 3 others
No phase
30 of 67
3 open now
Primary completion
2032-07
later than 9 of 11 live
Registered
38th of 67
by date

Among the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences, this one is the 2nd largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2017, is one of 30 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 38th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies in Breast Neoplasms by Wake Forest University Health Sciences are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Breast Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

This study is being done to see if patients receiving chemotherapy for breast cancer affects the heart, the ability to exercise and fatigue when compared to patients who do not have cancer.

Read the detailed description

840 women aged ≥18 years old scheduled to receive chemotherapy for Stage I-III breast cancer and a comparison population of 160 women without cancer (1,000 total). Equal numbers of women will be recruited aged \< 52 vs. > 52. At baseline, innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers will be collected.

Measurements will be repeated at 3±1, 12±2 and 24±2 months. This study will assess the relevance of pre-existing factors such as age, black/white race, hypertension, smoking (yes/no), diabetes, coronary artery disease, menopause status, CV medications, and physical activity on the study outcomes. Also, this study will assess dynamic change in modifiable CV risk factors (including BMI, blood pressure, serum lipids, serum glucose, physical activity, psychosocial factors, lifestyle behaviors), and the cancer treatment including chemotherapy, radiation therapy, immunotherapy, and surgery.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast Cancer
  • Fatigue
  • Cardiovascular Events
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Women with Stage I - III Breast Cancer:

  • Stage I-III female breast cancer (including inflammatory and newly diagnosed or locally recurrent breast cancer) but not breast cancer being treated with curative intent
  • > 18 years old
  • Scheduled to receive chemotherapy and/or estrogen antagonist aromatase inhibitors (anastrozole [Arimidex], letrozole [Femara], exemestane [Aromasin]).
  • Able to hold breath for 10 seconds
  • performance status 0 -2
  • Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting
  • Able to exercise on a treadmill or stationary cycle
  • Participants in other ongoing clinical trials are eligible for this study

Exclusion Criteria for Women with Stage I-III Breast Cancer:

  • Those with ferromagnetic cerebral aneurysm clips or other intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices (patients with tissue expanders will not be excluded)
  • If previously measured, known \<50%
  • Symptomatic claustrophobia
  • Unable to provide
  • At the beginning of the study, pregnant women and women who are breast-feeding will not be enrolled.
  • Severe pulmonary hypertension
  • Within the past 6 months:

    • Acute pulmonary embolus
    • Deep vein thrombosis
  • Within the past month:

    • Heart attack
    • Unstable or stable angina (cardiac chest pain)
    • Left main coronary artery disease
    • Symptomatic heart failure
    • Uncontrolled hypertension (SBP > 180 mm Hg or DBP > 120 mm Hg)
    • Severe valvular heart disease
    • Uncontrolled metabolic disease (diabetes with fasting BS >300 mg/dl, thyrotoxicosis, myxedema)
    • Aortic aneurism (>45 mm diameter) or aortic dissection
    • Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise
    • Hypertrophic obstructive cardiomyopathy
  • Patient does not understand English

Inclusion Criteria for Women Free of Cancer for Comparison:

  • Healthy female without known coronary artery disease > 18 years old
  • Able to hold breath 10 seconds
  • ECOG performance status = 0 or 1
  • Able to walk at least 2 blocks without chest pain, dyspnea, shortness of breath or fainting
  • Able to exercise on a treadmill or stationary cycle
  • No personal history of cancer other than superficial skin cancers
  • Has never received chemotherapy, radiation therapy, immunotherapy, or had breast cancer related surgery
  • If previously measured, LVEF ≥ 50%

Exclusion Criteria for Women Free of Cancer for Comparison:

  • Inflammatory conditions such as lupus or inflammatory bowel disease
  • Overt coronary artery disease or heart failure
  • Those with ferromagnetic cerebral aneurysm clips or other intracranial metal; pacemakers, defibrillators, functioning neurostimulator devices or other implanted non-compatible MRI devices
  • Symptomatic claustrophobia
  • Unable to provide informed consent
  • At the beginning of the study, pregnant women or women who are breast feeding will not be enrolled.
  • Severe pulmonary hypertension
  • Within the past 6 months:

    • Acute pulmonary embolus
    • Deep vein thrombosis
  • Within the past month:

    • Heart attack
    • Unstable or stable angina (cardiac chest pain)
    • Left main coronary artery disease
    • Symptomatic heart failure
    • Uncontrolled hypertension (SBP > 180 mm Hg or DBP > 120 mm Hg)
    • Severe valvular heart disease
    • Uncontrolled metabolic disease (diabetes with fasting BS >300 mg/dl, thyrotoxicosis, myxedema)
    • Aortic aneurism (>45 mm diameter) or aortic dissection
    • Uncontrolled slow or fast heart rhythm causing symptoms or hemodynamic compromise
    • Hypertrophic obstructive cardiomyopathy
  • Patient does not understand English
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
403 participants (actual)

Study arms

  • Experimental
    Breast Cancer Patients

    Breast cancer patients receiving non-anthracycline or anthracycline chemotherapy Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, on 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers. Measurements will be repeated at 3±1, 12±2 and 24±2 months after initiation of chemotherapy treatment.

    Diagnostic Test: Cardiac MRI

  • Experimental
    Non-Cancer Controls

    Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months. Baseline: Collect innovative MRI measures of CV function (LV and aorta); measurements of submaximal (6-minute walk) and, 45% of the cohort, maximal (peak VO2) exercise capacity; questionnaire data to assess fatigue and behavioral and psychosocial risk factors; and biomarkers. Measurements will be repeated at 3±1, 12±2 (after the completion of radiation) and 24±2 months after initiation of baseline activities.

    Diagnostic Test: Cardiac MRI

Interventions

  • Diagnostic testCardiac MRI

    Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months. Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months.

06

What researchers measure

Primary outcomes

  1. FACT-Fatigue

    Participants rate the degree to which each item applies in the past 7 days prior to Baseline using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.

    Time frame: Baseline

  2. Change in FACT-Fatigue Results

    Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.

    Time frame: Baseline and 3 months

  3. Change in FACT-Fatigue Results

    Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.

    Time frame: Baseline, 3 months and 12 months

  4. Change in FACT-Fatigue Results

    Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.

    Time frame: Baseline, 3 months, 12 months and 24 months

  5. Change in MRI Exam Results

    The exam will measure left ventricular volumes, ejection fraction, myocardial strain/strain rate, mass, mapping, aortic pulse wave velocity and aortic wall thickness. The exam will take 10 - 15 minutes to complete.

    Time frame: Baseline, 3 months and 24 months

  6. Change in 6 Minute Walk Results

    The purpose of this test is to find out how far the participant can walk in 6 minutes.

    Time frame: Baseline, 3 months, 12 months and 24 months

Secondary outcomes

  1. Cohen's 4-item Perceived Stress Scale (PSS)

    A summed scale asking how often over the prior two weeks four aspects of stress were experienced (1=never to 5=very often) o weeks four aspects of stress were experienced (1=never to 5=very often)

    Time frame: Baseline, 3 months, 12 months, and 24 months

  2. Cook-Medley Hostility Scale

    A 14-item scale used to assess the effect of hostility associated with cardiovascular risk factors. Minimum Score: 0 Maximum Score: 13 Higher values indicate greater hostility.

    Time frame: Baseline

  3. Changes in FACT-Fatigue Results

    Participants rate the degree to which each item applies in the past 7 days using a 5-point scale. Scores range from 0-52, with higher scores indicating greater fatigue.

    Time frame: Baseline, 3 months, 12 months, and 24 months

  4. 6 Minute Walk Results

    The purpose of this test is to find out how far the participant can walk in 6 minutes.

    Time frame: Baseline, 3 months, 12 months and 24 months

  5. RAND MOS 36-item Short Form Health Survey (SF-36)

    SF-36 consists of 36 items measuring the following 8 domains: physical function, role limitations due to physical health problems, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional health problems, and mental health. These 8 domains also provide two summary scores.

    Time frame: Baseline, 3 months, 12 months and 24 months

  6. Center for Epidemiological Studies Depression Scale (CESD-10)

    Screening questionnaire assessing depressive symptoms during the last week

    Time frame: Baseline, 3 months, 12 months and 24 months

  7. Godin Leisure-Time Exercise Questionnaire (LTEQ)

    Main process measure of physical activity participation

    Time frame: Baseline, 3 months, 12 months and 24 months

  8. PACE Adult Sedentary Behaviors Survey

    Assess sedentary lifestyle behaviors

    Time frame: Baseline, 3 months, 12 months and 24 months

  9. PROMIS Short Form 8A Measure of Sleep Disturbance

    Assess time course and risk factors associated with sleep disturbance and fatigue Minimum Score: Raw: 8, T-score: 28.9 Maximum Score: Raw: 40, T-score: 76.5 Higher values represent greater sleep disturbance.

    Time frame: Baseline, 3 months, 12 months and 24 months

  10. PROMIS Applied Cognitive Abilities Short Form 8A and Applied Cognition General Concerns Short Form 8A

    Measurement of different aspects of cognitive functioning. PROMIS Applied Cognitive Abilities Short Form 8A \- Minimum Score: Raw: 8, T-score: 27.0 Maximum Score: Raw: 40, T-score: 64.8 Higher values represent better cognition. Applied Cognition General Concerns Short Form 8A \- Minimum Score: Raw: 8, T-score: 23.3 Maximum Score: Raw: 40, T-score: 62.7 Higher values represent better cognition.

    Time frame: Baseline, 3 months, 12 months and 24 months

  11. Walking Efficacy for Duration Scale

    Comprised of six items and will be included as a measure of exercise capacity

    Time frame: Baseline, 3 months, 12 months and 24 months

  12. Chair Stands - Measures Leg Strength

    Participants will be first asked to stand from a sitting position without using their arms. If they can perform the task, they will then be asked to stand up and sit down five times as quickly as possible. The time to complete the task will be recorded.

    Time frame: Baseline, 3 months, 12 months and 24 months

  13. Standing Balance Test

    Participants will be asked to maintain balance for up to 30 seconds in three positions characterized by a progressive narrowing of the base support.

    Time frame: Baseline, 3 months, 12 months and 24 months

  14. Gait Speed Test

    Participants will be instructed to start at a marked walking course with toes touching the start line and when cued to start, will begin walking at their ususal speed. The time to walk from the starting line to the end of the 4-meter walk will be recorded.

    Time frame: Baseline, 3 months, 12 months and 24 months

  15. Grip Strength

    Grip strength is assessed with an isometric handgrip dynamometer while the participant is sitting with the head facing straight ahead. The elbow should be bent at a 90 degree angle and the wrist should be at the mid-prone position.

    Time frame: Baseline, 3 months, 12 months and 24 months

  16. Range of Motion

    Range of motion at the shoulder joint will be assessed with shoulder flexion and shoulder abduction with a goniometer.

    Time frame: Baseline, 3 months, 12 months and 24 months

  17. KCCQ-12 Questionnaire

    Independently measures the patient's perception of their health status which includes heart failure symptoms (frequency and burden), physical and social limitations, and how their heart failure impacts their QOL within a 2-week recall period.

    Time frame: Baseline, 24 months

Other outcomes

  1. B-type natriuretic peptide (BNP)

    Serum BNP as a predictor of exercise intolerance

    Time frame: Baseline and 24 months

  2. Troponin - 1

    Acquired to determine associations between troponin levels during therapy and the onset of cardiac and vascular dysfunction, exercise capacity, and fatigue.

    Time frame: Baseline and 3 months

07

Study locations

66 sites
08

References and documents

Publications

  • Avis NE, O'Connell NS, Mihalko SL, Jordan JH, Ladd AC, Lesser GJ, Olson KC, Weaver KE, Dressler EV, Grizzard PJ, Levine B, Moore TL, Ky B, Hackney MH, Brubaker P, Reding KW, Lucas AR, Bellissimo MP, Moeller FG, Kitzman DW, Hamilton CA, Klepin HD, Yeboah J, Ntim W, Zaha VG, D'Agostino R Jr, Hundley WG. Long-Term Fatigue After Treatment for Breast Cancer. JAMA Netw Open. 2026 Aug 3;9(8):e2629862. doi: 10.1001/jamanetworkopen.2026.29862. PubMed 42611514 ↗
  • Mabudian L, Reding K, D'Agostino RB Jr, Heiston EM, Bellissimo MP, Olson K, Ntim WO, Klepin HD, Dressler EV, Moore T, Jordan JH, O'Connell NS, Ladd A, Weaver KE, Ky B, Wagner LI, Hackney MH, Lesser GJ, Hundley WG; UPBEAT Study Team. The relationship between body composition and left ventricular performance in women with breast, lymphoma, or sarcoma cancer. Cardiooncology. 2024 Jun 6;10(1):34. doi: 10.1186/s40959-024-00233-1. PubMed 38845066 ↗
  • Garg R, D'Agostino RB Jr, O'Connell N, Lesser GJ, Salloum FN, Hines AL, Melendez GC, Jordan JH, Ky B, Wagner LI, Sutton AL, Bottinor W, Olson KC, Ladd AC, Hundley WG; UPBEAT Study Team. Hypertension Severity and Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (WF-97415 UPBEAT). Hypertension. 2024 Jun;81(6):1365-1373. doi: 10.1161/HYPERTENSIONAHA.123.21817. Epub 2024 Apr 18. PubMed 38634292 ↗
  • Bellissimo MP, Canada JM, Jordan JH, Ladd AC, Reding KW, Moore TL, Ntim WO, Heiston EM, Brubaker P, Mihalko SL, D'Agostino R Jr, O'Connell N, Ky B, Wagner LI, Hackney MH, Weaver KE, Lesser GJ, Avis NE, Sutton AL, Lucas AR, Franco RL, Fuemmeler BF, Salloum FN, Hundley WG; UPBEAT Study Group. Physical Activity During Breast Cancer Therapy Associates With Preserved Exercise Capacity and Cardiac Function (WF97415). JACC CardioOncol. 2023 Mar 21;5(5):641-652. doi: 10.1016/j.jaccao.2022.12.011. eCollection 2023 Oct. PubMed 37969655 ↗
  • Bellissimo MP, Canada JM, Jordan JH, Ladd AC, Heiston EM, Brubaker P, Mihalko SL, Reding K, D Agostino R, O Connell N, Hackney MH, Weaver KE, Lesser GJ, Avis NE, Hundley WG. Changes in Physical Activity, Functional Capacity, and Cardiac Function during Breast Cancer Therapy. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1509. doi: 10.1158/1055-9965.EPI-22-0470. PubMed 35775211 ↗

Individual participant data

Plan to share: Yes — Wake Forest NCORP Research Base is committed to following the NIH Statement on Sharing Research Data (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-032.html). As of July 2018, the WF NCORP RB signed an agreement with NCI to contribute de-identified data and data dictionaries from clinical trials conducted through our RB to the NCI NCTN/NCORP data archive within 6 months of primary and non-primary publications of phase II/III and phase III trials to https://nctn-data-archive.nci.nih.gov/. This will become the primary means for sharing raw data, and we will adhere to the guidelines spelled out in the NCTN/NCORP Data Archive Usage Guide. De-identified data from studies not covered by the agreement (e.g., phase II and observational studies) will be made available upon request. All data files will be de-identified. De-identification procedures will meet the HIPAA criteria as detailed in the Code of Federal Regulations, Part 45, Section 164.514.

Time frame: 6 months after publication for a 2 year duration

Access criteria: upon request to NCORP@wakehealth.edu

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jul 2032, 180 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 180 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: primary completion Jul 2034 → Jul 2032 and completion Jul 2034 → Jul 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2016
First posted
Jun 7, 2016
StartActual
Jul 21, 2017
Primary completionEst.
Jul 31, 2032was Jul 2034
CompletionEst.
Jul 31, 2032was Jul 2034
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 31, 2034→Jul 31, 2032
Sep 28, 2026
Study completion
Jul 31, 2034→Jul 31, 2032
Sep 28, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42611514 ↗
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42611514 ↗
    Primary completion Jul 31, 2034→Jul 31, 2032
    Study completion Jul 31, 2034→Jul 31, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02791581
Responsible party
Sponsor
First posted
Jun 7, 2016
Start date
Jul 21, 2017
Primary completion
Jul 31, 2032 (estimated)
Completion
Jul 31, 2032 (estimated)
Last update
Sep 28, 2026

Study contacts

Gregory Hundley, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion